Juan Jaen Sells 20,067 Shares of Arcus Biosciences (NYSE:RCUS) Stock

Arcus Biosciences, Inc. (NYSE:RCUS) President Juan Jaen sold 20,067 shares of the firm’s stock in a transaction dated Friday, July 10th. The shares were sold at an average price of $28.62, for a total transaction of $574,317.54. Following the transaction, the president owned 822,240 shares of the company’s stock, valued at approximately $23,532,508.80. This trade represents a 2.38% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Arcus Biosciences Stock Performance

Shares of RCUS opened at $28.43 on Wednesday. The company has a debt-to-equity ratio of 0.19, a current ratio of 4.04 and a quick ratio of 4.04. The firm’s 50 day moving average is $26.03 and its 200-day moving average is $23.56. Arcus Biosciences, Inc. has a 12-month low of $8.84 and a 12-month high of $31.74. The stock has a market capitalization of $3.58 billion, a P/E ratio of -8.94 and a beta of 0.80.

Arcus Biosciences (NYSE:RCUS) last released its earnings results on Tuesday, May 5th. The company reported ($1.02) EPS for the quarter, missing the consensus estimate of ($0.92) by ($0.10). The business had revenue of $17.00 million for the quarter, compared to analyst estimates of $29.48 million. Arcus Biosciences had a negative net margin of 156.36% and a negative return on equity of 68.97%. The firm’s revenue for the quarter was down 39.3% on a year-over-year basis. During the same period in the prior year, the company earned ($1.14) earnings per share. Equities research analysts anticipate that Arcus Biosciences, Inc. will post -3.66 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

RCUS has been the subject of a number of recent research reports. Morgan Stanley increased their price objective on Arcus Biosciences from $20.00 to $22.00 and gave the company an “equal weight” rating in a research report on Monday, May 11th. Wall Street Zen cut Arcus Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Truist Financial started coverage on Arcus Biosciences in a research report on Monday, May 18th. They set a “buy” rating and a $35.00 target price on the stock. Lifesci Capital started coverage on Arcus Biosciences in a report on Thursday, June 4th. They set an “outperform” rating and a $46.00 target price for the company. Finally, Wedbush increased their price target on Arcus Biosciences from $37.00 to $41.00 and gave the company an “outperform” rating in a research report on Thursday, April 2nd. Eight analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $35.10.

Institutional Investors Weigh In On Arcus Biosciences

Several hedge funds have recently made changes to their positions in RCUS. Hantz Financial Services Inc. lifted its position in shares of Arcus Biosciences by 121.9% in the 4th quarter. Hantz Financial Services Inc. now owns 1,604 shares of the company’s stock valued at $38,000 after acquiring an additional 881 shares in the last quarter. T. Rowe Price Investment Management Inc. purchased a new position in Arcus Biosciences during the 4th quarter worth approximately $39,000. KBC Group NV acquired a new stake in Arcus Biosciences during the 1st quarter valued at $50,000. GAMMA Investing LLC raised its stake in Arcus Biosciences by 17.5% during the 4th quarter. GAMMA Investing LLC now owns 3,230 shares of the company’s stock valued at $77,000 after purchasing an additional 482 shares during the period. Finally, Royal Bank of Canada lifted its holdings in shares of Arcus Biosciences by 14.6% in the first quarter. Royal Bank of Canada now owns 4,758 shares of the company’s stock valued at $102,000 after purchasing an additional 607 shares in the last quarter. Hedge funds and other institutional investors own 92.89% of the company’s stock.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.